Interview With Douglas K. Gordon

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
Leary speculates on…

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?

The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?

Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.

The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.

Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.

Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/

One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/

A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011

#Mindmed #kevinoleary #psychedelicstocks

So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.

Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.

Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.

So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.

Timestamps:
0:00 – Intro
1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
6:05 – MindMed catalyst #1 – Atai’s IPO
7:37 – PSIL ETF coming soon
9:58 – Phase 2a results for MindMed’s Project LUCY
11:38 – Project LUCY starting Phase2b in Q4 this year
12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
13:08 – Completion of Phase 1 LSD Neutralizer Study

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Links to Clinical trials :

https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY

https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY

https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedNasdaq #MindMedstock

Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w

What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.

This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#MindMed #MNMD #PsychedelicStocks

In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.

ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.

The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.

This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.

In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.

To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/

#psychedelics #therapy #magicmushrooms